Silvia Martin Lluesma

Advanced Therapies Manager at Vall d'Hebron Institute of Oncology (VHIO)

Silvia Martín Lluesma is an esteemed associate professor at Universidad CEU San Pablo, specializing in Genetic Engineering and Cell Therapy within the Faculty of Medicine since September 2019. Simultaneously, Silvia directs the Advanced Therapies Program at Vall d´Hebron Institute of Oncology, focusing on academic cell therapy trials and leading clinical trials development for advanced therapies in the EU. Previous roles include head of the Clinical Development Unit at CHUV | Lausanne University Hospital and experiences as a project manager and resident doctor at Hôpitaux Universitaires de Genève. Silvia's early academic career encompasses research positions at CNIO, University of Geneva, and Max Planck Institute for Biochemistry, contributing significantly to projects in cancer therapeutics and molecular biology. Academic qualifications include an M.D. and a Ph.D. in Medicine and Cellular and Molecular Biology respectively, alongside a master's degree in Marketing and an executive development program in Health and Pharmaceutical Industry Management.

Location

Madrid, Spain

Links


Org chart

No direct reports

Teams

This person is not in any teams


Offices


Vall d'Hebron Institute of Oncology (VHIO)

Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO) has established itself as a cancer research center of proven excellence internationally. It is thanks to Josep's directorship and VHIO's optimal organizational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease. Located within the Vall d´Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d´Hebron University Hospital physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients. VHIO's pioneering model and programs, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread and more effectively treating even the most undruggable tumour types. VHIO's translation toward precision oncology.


Industries

Headquarters

Spain

Employees

201-500

Links